CVS HEALTH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.6 USD | +6.35% |
|
+7.31% | -24.52% |
| 30/05 | JPMorgan Adjusts Price Target on CVS Health to $86 From $101 | MT |
| 30/05 | Baird Initiates CVS Health With Neutral Rating, $61 Price Target | MT |
| Sales 2024 * | 37TCr 30,76900Cr | Sales 2025 * | 39TCr 32,29100Cr | Capitalization | 7.48TCr 6,24100Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 758.3Cr 63TCr | Net income 2025 * | 887.9Cr 74TCr | EV / Sales 2024 * | 0.34 x |
| Net Debt 2024 * | 4.97TCr 4,14900Cr | Net Debt 2025 * | 4.62TCr 3,85200Cr | EV / Sales 2025 * | 0.31 x |
| P/E ratio 2024 * |
10.5
x | P/E ratio 2025 * |
8.77
x | Employees | 2,59,500 |
| Yield 2024 * |
4.46% | Yield 2025 * |
4.65% | Free-Float | 70.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on CVS Health Corporation
More recommendations
More press releases
More news
| 1 day | +6.35% | ||
| 1 week | +7.31% | ||
| 1 month | -11.98% | ||
| 3 months | -19.86% | ||
| 6 months | -12.29% | ||
| Current year | -24.52% |
1 week
52.77
59.62
1 month
52.7759.73
Current year
52.7783.25
1 year
52.7783.25
3 years
52.77111.25
5 years
52.04111.25
10 years
51.72113.65
| Managers | Title | Age | Since |
|---|---|---|---|
Karen Lynch
CEO | Chief Executive Officer | 61 | 28/18/28 |
Thomas Cowhey
DFI | Director of Finance/CFO | 51 | 01/22/01 |
Tilak Mandadi
CTO | Chief Tech/Sci/R&D Officer | - | 25/22/25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anne Finucane
BRD | Director/Board Member | 71 | 20/11/20 |
Fernando Aguirre
BRD | Director/Board Member | 66 | 28/18/28 |
Mary Schapiro
BRD | Director/Board Member | 68 | 10/17/10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.92% | 17 M€ | +6.09% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 59.6 | +6.35% | 22,366,748 |
| 30/24/30 | 56.04 | +4.42% | 16,154,336 |
| 29/24/29 | 53.67 | +0.07% | 16,543,442 |
| 28/24/28 | 53.63 | -3.44% | 14,387,106 |
| 24/24/24 | 55.54 | -0.20% | 11,725,739 |
Delayed Quote Nyse, May 01, 2024 at 01:30 am IST
More quotes
CVS Health Corporation is one of the leading American suppliers of health products and services. Net sales (including intragroup) break down by activity as follows:
- medical insurance plan management services (45.6%; Pharmacy Benefit Management): administrative management (reimbursement management, patient claim processing, etc.), drug distribution, decision-making information, sales of medical information management services, etc.;
- retail distribution (28.5%): sale of prescription pharmaceutical products, OTC products, beauty and cosmetics products. At the end of 2023, products are marketed primarily via a network of more than 9,000 outlets and via the Internet. In addition, the group offers healthcare services through more than 1,000 clinics (MinuteClinic®);
- medical benefits management (25.8%);
- other (0.1%).
Calendar
31/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
59.6
USD
Average target price
70.17
USD
Spread / Average Target
+17.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.52% | 7.48TCr | |
| +25.52% | 8.9TCr | |
| -5.56% | 2.5TCr | |
| +4.31% | 1.79TCr | |
| -14.25% | 1.64TCr | |
| +2.97% | 1.58TCr | |
| +70.11% | 1.31TCr | |
| +79.20% | 1.32TCr | |
| +40.44% | 1.29TCr | |
| +24.51% | 1.27TCr |
- Stock Market
- Equities
- CVS Stock
